Plain-English translation of NCT06611839 on ClinicalTrials.gov ↗ ·
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing whether three medications—venetoclax, ivosidenib, and azacitidine—work well together to treat a specific type of blood cancer called acute myeloid leukemia (AML) in patients who have an IDH1 genetic mutation. The three medications work in different ways: ivosidenib targets the genetic mutation itself, venetoclax helps cancer cells die naturally, and azacitidine helps restore normal gene function. Early research suggests this combination may help more patients go into remission and live longer.
Most patients with this genetic form of AML are older or too frail to receive traditional intensive chemotherapy. Recent studies show this three-drug combination is very effective and safe in patients who cannot tolerate chemotherapy, so researchers want to confirm these results in a larger group of patients who are fit enough to receive more intensive treatment.
You likely qualify if…
You likely don't qualify if…
You will receive the three medications in 28-day treatment cycles: venetoclax and ivosidenib taken by mouth daily, and azacitidine given as injections or infusions for 7 days each cycle. After completing the initial treatment phase, you will receive additional consolidation therapy with a higher dose of chemotherapy. You will have regular clinic visits and blood tests to monitor how well the treatment is working and check for side effects. The study will follow your progress for up to 27 months or longer to see how long your remission lasts.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China